Novel medical use of selective cb1-receptor antagonists

Details Novel medical use of selective cb1-receptor antagonists Novel medical use of selective cb1-receptor antagonists

A - Human Necessities

61

K

A61K 31/435 (2006.01) A61K 31/05 (2006.01) A61K 31/352 (2006.01) A61K 31/397 (2006.01) A61K 31/4045 (2006.01) A61K 31/415 (2006.01) A61K 31/4164 (2006.01) A61P 3/04 (2006.01) A61P 9/00 (2006.01) A61P 25/18 (2006.01)

Patent

CA 2537535

The present invention relates to a novel medical use of selective CB1 receptor antagonistic compounds. Said compounds are particularly suitable in the manufacture of medicaments for the treatment and/or prophylaxis of CB1 receptor related diseases in juvenile patients (pediatric treating), e.g. in particular obesity in juvenile patients, and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The CB1 receptor antagonistic compounds suitable according to the invention are elucidated in more detail in the description.

L'invention concerne une nouvelle utilisation médicale de composés antagonistes sélectifs du récepteur CB¿1?. Lesdits composés conviennent particulièrement pour la préparation de médicaments destinés au traitement ou à la prévention de maladies liées au récepteur CB¿1? chez les patients juvéniles (traitements pédiatriques), p. ex. l'obésité spécifique des patients juvéniles, et/ou pour le traitement ou la prévention de l'obésité d'origine médicamenteuse chez l'enfant ainsi que chez l'adolescent. Les composés antagonistes du récepteur CB¿1? sont définis de manière plus détaillée dans le descriptif.

Affiliated with

Also associated with

Rating

Novel medical use of selective cb1-receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel medical use of selective cb1-receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel medical use of selective cb1-receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1603433